Emergent BioSolutions Inc.
Emergent BioSolutions Inc. (EBS) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
ebs · stock forecast · 15 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 15 Wall Street analysts in the past 3 months
Buy
15 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$12.00
Consensus
$12.00
+46.4% upside
Low
$12.00
Median: $12 · Last Close: $8.20
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $8.01 | ↓ 2.28% |
1-day model range: $7.96–$8.06. Peak: $8.06 (-2.28%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $5 | -33.8% |
| 2028 | $4 | -46.1% |
| 2029 | $4 | -51.6% |
| 2030 | $4 | -54.4% |
| 2031 | — | -55.8% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · EBS · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-03-09 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-12-16 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-09-03 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-04-01 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-03-21 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-03-04 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-01-21 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-01-10 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-11-07 | Benchmark | Maintains | Buy→Buy |
| 2024-09-13 | Rodman & Renshaw | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Emergent BioSolutions Inc. (EBS) stock. Of the recent 66 rating actions, 5 were upgrades and 8 were downgrades. 15 analysts currently cover EBS.
Analyst Recommendation Trends
EBS analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$809M
↓ 9.3% YoY
Revenue Next Year
$733M
↓ 9.4% YoY
EPS This Year
$2.05
EPS Next Year
$0.33
↓ 84.1% YoY
EPS ForecastReported vs Estimated
Analysts forecast EBS EPS of $2.05 for the current fiscal year, based on estimates from 1 analysts. The EBS revenue forecast is $809M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The EBS stock forecast is supported by two independent data sources: analyst consensus ratings from 15 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus EBS price target is $12.00 (+46.4% upside), with an analyst consensus of Buy.
The EBS short-term stock prediction for tomorrow is $8.01 (-2.28%). The EBS stock price prediction for 2027 estimates an average of $5. The EBS stock prediction for 2030 projects a range of $3–$4.
Emergent BioSolutions Inc. trades on NYSE under the ticker EBS. The EBS stock outlook for 2027 is broadly positive, supported by a Buy consensus among 73% of covering analysts.
Frequently asked questions
EBS forecast · 8 questionsAccording to 15 Wall Street analysts, the average 12-month EBS price target is $12.00, with a high forecast of $12.00 and a low of $12.00. The median price target is shown in the chart above when available. This implies +46.4% potential upside from the current price of $8.20.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.